Incident cardiovascular disease by clustering of favourable risk factors in type 1 diabetes: the EURODIAB Prospective Complications Study

被引：0
|
作者：
Soraya Soulimane
Beverley Balkau
Yakima D. Vogtschmidt
Monika Toeller
John H. Fuller
Sabita S. Soedamah-Muthu
机构：
[1] Tilburg University,Center of Research on Psychological disorders and Somatic diseases (CoRPS), Department of Medical and Clinical Psychology
[2] Université Paris-Saclay,Clinical Epidemiology
[3] UVSQ,Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences
[4] Inserm,Institute for Food, Nutrition and Health
[5] CESP,Department of Epidemiology and Public Health
[6] University of Reading,undefined
[7] University of Reading,undefined
[8] Heinrich Heine University Düsseldorf,undefined
[9] University College London,undefined
来源：
Diabetologia | 2022年 / 65卷
关键词：
Cardiovascular health metrics; HbA; Risk factors; Type 1 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1169 / 1178
页数：9
相关论文
共 50 条
  • [31] Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study
    M. Porta
    A.-K. Sjoelie
    N. Chaturvedi
    L. Stevens
    R. Rottiers
    M. Veglio
    J. H. Fuller
    Diabetologia, 2001, 44 : 2203 - 2209
  • [32] Risk Factors for Cardiovascular Disease in Type 1 Diabetes
    Nathan, David M.
    Bebu, Ionut
    Braffett, Barbara H.
    Lachin, John M.
    Orchard, Trevor J.
    Cowie, Catherine C.
    Lopes-Virella, Maria
    Schutta, Mark
    DIABETES, 2016, 65 (05) : 1370 - 1379
  • [33] Genetic Risk Factors for Incident Cardiovascular Disease in Type 2 Diabetes Patients
    Kwak, Soo Heon
    Mercader, Josep M.
    Leong, Aaron
    Porneala, Bianca
    Wu, Peitao
    Cole, Joanne B.
    Merino, Jordi
    Park, Kyong Soo
    Cho, Nam H.
    Dupuis, Josee
    Florez, Jose C.
    Meigs, James B.
    DIABETES, 2020, 69
  • [34] Circulating and urinary transforming growth factor β1, Amadori albumin, and complications of type 1 diabetes -: The EURODIAB Prospective Complications Study
    Chaturvedi, N
    Schalkwijk, CG
    Abrahamian, H
    Fuller, JH
    Stehouwer, CDA
    DIABETES CARE, 2002, 25 (12) : 2320 - 2327
  • [35] Incidence and determinants of microalbuminuria in Type 1 diabetes: the Italian cohort of the EURODIAB Prospective Complications study.
    Bandinelli, S
    Penno, G
    Pucci, L
    Miccoli, R
    Del Prato, S
    Reboldi, P
    Santeusanio, F
    DIABETOLOGIA, 2002, 45 : A360 - A361
  • [36] Association of diet and lifestyle with glycated haemoglobin in type 1 diabetes participants in the EURODIAB prospective complications study
    S N Balk
    D A J M Schoenaker
    G D Mishra
    M Toeller
    N Chaturvedi
    J H Fuller
    S S Soedamah-Muthu
    European Journal of Clinical Nutrition, 2016, 70 : 229 - 236
  • [37] Diabetic retinopathy is associated with mortality and cardiovascular disease incidence - The EURODIAB prospective complications study
    van Hecke, MV
    Sjolie, AK
    Dekker, JM
    Kofinis, A
    Stehouwer, CDA
    Rottiers, R
    Polak, BCP
    Porta, M
    Fuller, JH
    Chaturvedi, N
    DIABETES CARE, 2005, 28 (06) : 1383 - 1389
  • [38] Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)
    Soedamah-Muthu, S. S.
    Chaturvedi, N.
    Pickup, J. C.
    Fuller, J. H.
    DIABETOLOGIA, 2008, 51 (03) : 493 - 501
  • [39] Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study
    Giorgino, F
    Laviola, L
    Perin, PC
    Solnica, B
    Fuller, J
    Chaturvedi, N
    DIABETOLOGIA, 2004, 47 (06) : 1020 - 1028
  • [40] Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)
    S. S. Soedamah-Muthu
    N. Chaturvedi
    J. C. Pickup
    J. H. Fuller
    Diabetologia, 2008, 51 : 493 - 501
12345